The 36-month beta value for MRVI is also noteworthy at -0.08. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 6 rating it as “overweight,” 6 rating it as “hold,” and 0 rating it as “sell.”
The public float for MRVI is 117.54M, and at present, short sellers hold a 6.99% of that float. The average trading volume of MRVI on November 27, 2024 was 1.78M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MRVI) stock’s latest price update
Maravai LifeSciences Holdings Inc (NASDAQ: MRVI)’s stock price has plunge by 6.24relation to previous closing price of 5.29. Nevertheless, the company has seen a 21.38% surge in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-12 that SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) — Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in November.
MRVI’s Market Performance
MRVI’s stock has risen by 21.38% in the past week, with a monthly drop of -22.05% and a quarterly drop of -38.65%. The volatility ratio for the week is 9.59% while the volatility levels for the last 30 days are 8.57% for Maravai LifeSciences Holdings Inc The simple moving average for the last 20 days is -7.02% for MRVI stock, with a simple moving average of -30.49% for the last 200 days.
Analysts’ Opinion of MRVI
Wells Fargo gave a rating of “Overweight” to MRVI, setting the target price at $10 in the report published on August 28th of the current year.
MRVI Trading at -22.18% from the 50-Day Moving Average
After a stumble in the market that brought MRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.36% of loss for the given period.
Volatility was left at 8.57%, however, over the last 30 days, the volatility rate increased by 9.59%, as shares sank -20.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.18% lower at present.
During the last 5 trading sessions, MRVI rose by +21.38%, which changed the moving average for the period of 200-days by +2.18% in comparison to the 20-day moving average, which settled at $6.04. In addition, Maravai LifeSciences Holdings Inc saw -14.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRVI starting from DeFord John A, who purchase 17,500 shares at the price of $5.75 back on Nov 12 ’24. After this action, DeFord John A now owns 70,046 shares of Maravai LifeSciences Holdings Inc, valued at $100,625 using the latest closing price.
HULL CARL, the of Maravai LifeSciences Holdings Inc, purchase 175,000 shares at $5.64 during a trade that took place back on Nov 11 ’24, which means that HULL CARL is holding 175,000 shares at $987,000 based on the most recent closing price.
Stock Fundamentals for MRVI
Current profitability levels for the company are sitting at:
- -0.71 for the present operating margin
- 0.44 for the gross margin
The net margin for Maravai LifeSciences Holdings Inc stands at -0.81. The total capital return value is set at -0.16. Equity return is now at value -51.98, with -12.67 for asset returns.
Based on Maravai LifeSciences Holdings Inc (MRVI), the company’s capital structure generated 0.6 points at debt to capital in total, while cash flow to debt ratio is standing at 0.06. The debt to equity ratio resting at 1.51. The interest coverage ratio of the stock is -3.77.
Currently, EBITDA for the company is 712.41 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 2.82. The receivables turnover for the company is 9.59for trailing twelve months and the total asset turnover is 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.74.
Conclusion
In summary, Maravai LifeSciences Holdings Inc (MRVI) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
